Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual pathway inhibition with aspirin and rivaroxaban in peripheral artery disease
NL-OMON28220Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of aspirin and rivaroxaban in arteriosclerosis obliterans (2 arms), sponsored by Radboud University Medical Center. Started Jun 2020; status: active, not recruiting.
02
Drugs
aspirinrivaroxaban
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on NL-OMON28220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28220.